

Additional File 5: Summary of patients who received two doses of study drug and were excluded from the study analysis

Characteristic	Participant						
	01-001	01-061	01-062	01-063	01-066	01-069	01-070
Age (mo.)	0.2	176.2	1.1	13.3	1.8	147.9	3.1
Weight (kg)	3.8	195.0	4.9	9.4	11.1	54.6	16.2
Sex	Male	Male	Male	Male	Male	Female	Male
Admission season	Winter	Winter	Winter	Winter	Spring	Spring	Spring
Diagnosis	Surgical, Cardiac	Medical	Medical	Surgical, Cardiac	Medical	Medical	Medical
Mechanical ventilation^a	Yes	No	No	Yes	No	Yes	Yes
PICU length of stay (hours)	212	151	179	354	184	189	289
Survival Status at PICU Discharge	Alive	Alive	Alive	Alive	Alive	Alive	Alive
Received catecholamines	Yes	No	No	Yes	No	Yes	Yes
Group Assignment	High Dose	Placebo	High Dose	High Dose	Placebo	High Dose	Placebo
Day 3 plasma 25(OH)D concentration, nmol/L (CHEO)	61.1	64.0	158.1	149.6	<32.0 ^c	59.1	55.8
Number of doses received^b	1.5	1.5	1	1	2	1.5	1.5
Day 7 25OHD, nmol/L (Research)	143.6	31.5	306.6	192.0	38.6	109.9	54.0
Hospital Discharge plasma 25OHD concentration, nmol/L (Clinical Sample)	99.5	73.3	163.5	129.3	25.0	75.0	37.0

^aDefined as endotracheal intubation

^bBased on Day 3 25OHD level; <50 nmol/L = 10000 IU/KG to a maximum of 400000IU; 50-75 nmol/L = 5000 IU/KG to a maximum of 400000IU; > 75 nmol/L = placebo is given

^cLower threshold for point of care device is 32.0 nmol/L. Values lower than 32.0 nmol/L reported as <32.0 nmol/L.

12 patients randomized to 2 dose regimen; 7 patients received 2 doses